相关临床试验
214
22 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1904
进行中（未招募）
20
9.3%
已完成
108
50.5%
尚未招募
2
0.9%
招募中
30
14.0%
暂停
2
0.9%
终止
33
15.4%
Unknown
2
0.9%
撤回
17
7.9%
暂无批准数据
- A phase 1 trial at Fox Chase Cancer Center and Temple University is combining the JAK2 inhibitor pacritinib with the PARP inhibitor talazoparib to treat myelofibrosis patients who no longer respond to standard therapies. - Early results show significant symptom improvement, with severe patients' symptom scores dropping to single digits within three months, alongside clear biological evidence of increased cancer cell death. - The treatment was well tolerated, with patients remaining on therapy for nearly a year without serious side effects requiring discontinuation or dose reduction. - Researchers plan to enroll 24 patients and use single-cell DNA sequencing to track which cancer cell populations persist, guiding future combination strategies.
- The Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP) launched its fifth cohort with 80 medical students training at 18 research institutions across the country. - The initiative, established by the Bristol Myers Squibb Foundation in 2020, is funded by Gilead Sciences, Amgen, Genentech, and AstraZeneca alongside the foundation. - Participants complete a six-week summer externship focused on community-engaged research, mentorship, and clinical trial design to improve representation in clinical trials. - The program's annual culminating symposium was held at Roosevelt University in Chicago, Illinois from July 9-11, 2026.
- OncoDaily Medical Journal, the official journal of the Immune Oncology Research Institute, has added 20 new editorial team members from 12 countries across two recent recruitment waves. - The new editors bring expertise spanning immuno-oncology, precision medicine, pediatric oncology, sarcoma, melanoma, and hereditary cancers, strengthening the journal's global reach. - Notable appointments include specialists from City of Hope, Fox Chase Cancer Center, Cleveland Clinic, and other leading cancer institutions worldwide. - The expansion aims to advance the journal's mission of bridging research, clinical practice, and education in oncology through high-quality, peer-reviewed content.
- ZBP1 is an innate immune sensor that detects Z-DNA/Z-RNA structures generated during genomic stress and triggers immunogenic necroptosis in tumor cells. - Therapeutic activation of the ZBP1–RIPK3–MLKL axis may convert immunologically "cold" tumors into "hot" tumors, enhancing immune checkpoint blockade efficacy. - Small-molecule drugs like JTE-607 analogs are being designed to mimic viral stress and induce Z-RNA formation without using live viruses. - Key challenges include identifying patient biomarkers, optimizing combination strategies, and minimizing inflammatory toxicity before clinical translation.
- The phase II A-DREAM/Alliance A032101 trial found that 41% of metastatic hormone-sensitive prostate cancer patients with exceptional response to ARPIs remained off androgen deprivation therapy at 18 months with testosterone recovery. - After a median follow-up of 26.9 months post-treatment interruption, 38.5% of patients still had not needed to resume any treatment, including those with high-volume disease. - Only one of four deaths during follow-up was attributed to prostate cancer, suggesting no negative cancer-related outcomes from the treatment break. - Investigators suggest that exceptional responders struggling with side effects could safely take a treatment break, though larger randomized trials are needed to establish definitive guardrails.
- SpotitEarly has formed a strategic partnership with Fox Chase Cancer Center to conduct multi-year clinical trials evaluating its breath-based cancer detection test in lung cancer patients. - The collaboration combines SpotitEarly's proprietary LUCID bio-AI hybrid platform, which uses trained canines and artificial intelligence to identify cancer odor signatures in breath samples. - Previous clinical studies involving over 1,300 participants demonstrated the platform's overall sensitivity of approximately 94% across four common cancers with strong early-stage performance. - This partnership follows SpotitEarly's recent collaboration with Hackensack Meridian Health, highlighting growing confidence in the company's innovative approach to early cancer detection.
- Fox Chase Cancer Center partners with Arima Genomics to become the first NCI-designated Comprehensive Cancer Center implementing 3D-genomics technology as standard protocol across multiple tumor types. - The collaboration integrates Arima's Hi-C based technology into diagnostic workflows for lymphoma and sarcoma through Aventa Lymphoma and Aventa FusionPlus tests. - Unlike conventional DNA sequencing, Arima's platform analyzes the 3D architecture of the entire genome, revealing structural changes that traditional testing methods may miss. - The partnership enables both clinical implementation and research opportunities to identify new drug targets and advance understanding of cancer biology.
- Dexamethasone prophylaxis significantly reduced grade 3/4 immune effector cell-associated neurotoxicity syndrome (ICANS) from 25% to 0% in patients receiving axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. - The steroid treatment did not compromise CAR-T cell efficacy, with comparable overall response rates (89% vs 75%) and survival outcomes between prophylaxis and control groups. - Peak absolute lymphocyte counts were significantly higher in dexamethasone-treated patients (750 vs 500 cells/μL), suggesting enhanced immune cell expansion rather than suppression. - These findings challenge previous concerns about steroid use potentially limiting CAR-T cell expansion and provide evidence for improved safety without efficacy trade-offs.
- Fox Chase Cancer Center's outpatient monitoring program significantly reduced hospital stays for patients receiving CAR-T and bispecific T-cell engager therapies without compromising safety. - More than half of patients receiving BiTE therapy avoided hospitalization entirely, while CAR-T patients experienced substantial reductions in total hospital stay. - The structured outpatient model requires patients to have caregivers, remain within 60 minutes of the cancer center, and undergo daily toxicity assessments during the monitoring period. - No adverse safety events or clinically significant delays in care were reported, demonstrating the program's safety and potential for widespread adoption.
- Researchers at Fox Chase Cancer Center found that measuring absolute lymphocyte count (ALC) can predict treatment outcomes in non-Hodgkin lymphoma patients receiving CAR-T cell therapy. - Higher baseline ALC and faster ALC increases within 10 days post-treatment were significantly linked to better progression-free survival, overall survival, and complete response rates. - This practical, low-cost biomarker could help clinicians quickly identify patients at risk of relapse and guide treatment decisions more effectively. - The study focused on patients receiving axicabtagene ciloleucel (Yescarta) therapy and represents the first identification of ALC increase rate as a treatment response marker.
